Y-mAbs Therapeutics, Inc.
YMAB
$4.73
-$0.18-3.67%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.41% | -9.74% | 9.86% | -1.58% | -25.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.41% | -9.74% | 9.86% | -1.58% | -25.71% |
| Cost of Revenue | 284.60% | -15.01% | -35.17% | 3.07% | 0.94% |
| Gross Profit | -12.53% | -8.96% | 22.87% | -2.11% | -27.54% |
| SG&A Expenses | 5.01% | 26.09% | 52.21% | 1.71% | 0.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.17% | -6.71% | 16.49% | 15.34% | -16.95% |
| Operating Income | -36.39% | -1.30% | -35.53% | -128.82% | -496.83% |
| Income Before Tax | -851.07% | 12.01% | -49.42% | -1.24% | -168.54% |
| Income Tax Expenses | -485.64% | 85.03% | -44.13% | -- | -- |
| Earnings from Continuing Operations | -587.25% | 9.67% | -46.76% | -3.74% | -185.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -587.25% | 9.67% | -46.76% | -3.74% | -185.39% |
| EBIT | -36.39% | -1.30% | -35.53% | -128.82% | -496.83% |
| EBITDA | -40.26% | -1.95% | -37.68% | -137.89% | -892.81% |
| EPS Basic | -569.47% | 11.71% | -45.60% | -3.49% | -185.28% |
| Normalized Basic EPS | -628.95% | 23.27% | -48.29% | -238.46% | -125.11% |
| EPS Diluted | -573.01% | 11.71% | -45.60% | -0.93% | -187.26% |
| Normalized Diluted EPS | -628.95% | 23.27% | -48.29% | -238.46% | -125.68% |
| Average Basic Shares Outstanding | 2.86% | 2.31% | 0.82% | 0.25% | -0.09% |
| Average Diluted Shares Outstanding | 2.86% | 2.31% | 0.82% | 0.25% | -2.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
